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Development of a human three-dimensional
organotypic skin-melanoma spheroidmodel for in vitro
drug testing
H Vo¨rsmann1, F Groeber2, H Walles3, S Busch4, S Beissert5, H Walczak6 and D Kulms*,1,5
Despite remarkable efforts, metastatic melanoma (MM) still presents with significant mortality. Recently, mono-chemotherapies
are increasingly replenished by more cancer-specific combination therapies involving death ligands and drugs interfering with
cell signaling. Still, MM remains a fatal disease because tumors rapidly develop resistance to novel therapies thereby regaining
tumorigenic capacity. Although genetically engineered mouse models for MM have been developed, at present no model is
available that reliably mimics the human disease and is suitable for studying mechanisms of therapeutic obstacles including cell
death resistance. To improve the increasing requests on new therapeutic alternatives, reliable human screening models are
demanded that translate the findings from basic cellular research into clinical applications. By developing an organotypic full
skin equivalent, harboring melanoma tumor spheroids of defined sizes we have invented a cell-based model that recapitulates
both the 3D organization and multicellular complexity of an organ/tumor in vivo but at the same time accommodates systematic
experimental intervention. By extending our previous findings on melanoma cell sensitization toward TRAIL (tumor necrosis
factor-related apoptosis-inducing ligand) by co-application of sublethal doses of ultraviolet-B radiation (UVB) or cisplatin, we
show significant differences in the therapeutical outcome to exist between regular two-dimensional (2D) and complex in vivo-like
3D models. Of note, while both treatment combinations killed the same cancer cell lines in 2D culture, skin equivalent-embedded
melanoma spheroids are potently killed by TRAILþ cisplatin treatment but remain almost unaffected by the TRAILþUVB
combination. Consequently, we have established an organotypic human skin-melanoma model that will facilitate efforts to
improve therapeutic outcomes for malignant melanoma by providing a platform for the investigation of cytotoxic treatments and
tailored therapies in a more physiological setting.
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Malignant melanoma is a highly aggressive cancer with
rapidly increasing incidence. The prognosis for patients with
metastatic melanoma (MM) is particularly poor with stage IV
patients having a median survival of B8±2 months.1
Malignant transformation of melanocytes involves stepwise
tumor progression. The early radial growth phase (RGP)
advances via the vertical growth phase (VGP), into highly
aggressive MM.2,3 The metastatic stage still represents the
major therapeutic challenge, as responders to conventional
chemotherapy are still below 20% for mono- and below 30%
for poly-chemotherapy.4–6 Therefore, alternative therapeutic
strategies are required, and the targeting of specific
activating mutations in melanoma has been of particular
interest,7–10 yet almost invariably, responders develop
therapy resistance.11
The majority of currently available data on human
melanoma have been obtained from two-dimensional (2D)
cultures of melanoma cell lines. Tumor cells, however, grow in
a three-dimensional (3D) environment in which intercellular
cross-talk exists between differentiated cancer cell sub-
populations as well as between cancer and non-transformed
neighboring host cells. Consequently, 3D skin reconstruction
models have recently become attractive preclinical testing
tools for novel therapeutic approaches, especially 3D models
that contain human MM cells.12 However, most current
models are limited to the dermal compartment of the skin that
contains MM nests consisting of only few cells and therefore
do not adequately recapitulate melanoma metastases. Here,
we develop a novel organotypic 3D human skin and
melanoma reconstruction model that closely resembles the
in vivo situation of cutaneous melanoma metastasis and
validate it by comparing the therapeutic effects of two TRAIL
(tumor necrosis factor-related apoptosis-inducing ligand)-
based combination therapies.
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In a previous 2D study employing 18 cell lines derived from
different tumor progression stages, we found most of the cell
lines to be TRAIL resistant.13 Irradiation with sublethal
ultraviolet-B radiation (UVB) synergistically rendered them
TRAIL sensitive by a mechanism involving caspase-3-
dependent cleavage of the X-linked inhibitor of apoptosis
protein (XIAP).13,14 Here, we find a similar, albeit less
pronounced cisplatin-mediated TRAIL sensitization of
melanoma cells in 2D culture. Strikingly, in the new 3D
skin-melanoma model developed herein, cisplatin became
substantially more active as a TRAIL sensitizer than UVB.
This diametric difference in responsiveness of melanoma
cells in 2D versus 3D culture to two related combinatorial
treatments exemplifies the need to develop more complex
preclinical model systems for human malignant melanoma.
Since 2D cultures so far have failed to provide successful
treatment strategies for most metastatic cancers, the 3D
model may more reliably predict clinical effectiveness of
novel therapeutic regimes to be taken to clinical trials.
Additionally, the model provides an excellent tool to
gain closer insights into intra-tumoral differentiation and
tumor–host interaction.
Results
3D full-thickness skin equivalents resemble normal
human skin. Successful treatment of metastasis can be
influenced by both, cellular cross-talk between tumor cells
and between tumor and host cells. To establish an in vivo-like
environment representing human skin, we seeded primary
keratinocytes on top of primary fibroblasts embedded into a
collagen I scaffold. Differentiation of keratinocytes was
achieved by culturing the skin equivalents at an air–liquid
interface for up to 17 days. Immunohistochemical examina-
tion of the 3D full-thickness skin equivalents revealed proper
epidermal stratification forming distinct layers of the epidermis
as seen in normal human skin (Figures 1a and b). While cells
from the basal epidermal layers stained positive for keratin 14,
the more differentiated cells from the supra-basal layer
stained positive for keratin 10 and involucrin. Highly
differentiated cells close to the stratum corneum were the
only ones that stained positive for filaggrin. Most importantly,
laminin 5 staining revealed that, just as in normal human
skin, a basal lamina was generated to physiologically
connect the epidermal to the dermal portion of the artificial
skin (lowest panel, Figures 1a and b). Consequently, we
generated a 3D in vivo human skin-like environment in vitro
which should prove useful to study primary dermal
melanoma metastasis.
Development of a 3D full-thickness skin-melanoma
metastasis model. To test whether these skin equivalents
are useful to study malignant melanoma in a 3D
environment, we inserted cell lines representing different
progression stages. Whereas SBCL2 (RGP) and WM-115
(VGP) cells formed nest-like structures in the epidermis
(black arrows) only metastatic 451-LU (MM) cells invaded
deeply into the dermis to form melanoma nests (Figure 1c),
indicating that the 3D skin equivalent provides an
organotypic environment in which melanoma cells can grow
according to their progression stage.
Although skin equivalents incorporating melanoma nests
could already be used to study therapeutic effectiveness, we
were bothered by three shortcomings of these types of
models: first, number and size of melanoma nests formed are
unpredictable; second, metastases in vivo are usually larger
than melanoma nests and exhibit a more complex intra-
tumoral diversity; third, due to the limited life span of tumor-nest
models, treatment is initiated early, and therefore, rather than
inducing regression of existing tumor nests, it interferes with
tumor outgrowth.
To overcome these limitations, we generated melanoma
spheroids of defined size and cell number to be inserted at
defined numbers into the organotypic skin equivalents. By
culturing 250 metastatic 451-LU cells in a hanging drop for
15 days,15 we reproducibly generated spheroids consisting of
viable melanoma cells presenting a compact structure with a
final diameter ofB500mm mimicking non-vascularized tumor
nodes, micrometastasis or inter-capillary micro regions of
solid tumors (Figure 2a).16,17
We next inserted a defined number of these spheroids (10)
into the dermal fibroblast/collagen I scaffold at day 1 of
model construction (Figure 2b), allowing them to grow and
co-develop during epidermal differentiation for 17 more days.
Thereby, we derived a novel 3D skin-melanoma spheroid
model that contained spheroids which had been cultured
in vitro for a total of 31 days in the context of artificial
organotypic skin.
Melanoma spheroids integrated into skin equivalents
recapitulate key features of human cutaneous
melanoma metastasis. Immunohistochemical analysis of
the skin-melanoma spheroid model revealed spheroids to
share many key features regarding histological appearance
and cellular distribution with non-vascularized human
cutaneous melanoma metastases in vivo (Figure 3). Two
sub-populations of cells are clearly discernible in skin-
embedded melanoma spheroids (Figure 3a). The peripheral
living sub-population harbors about 70% proliferating (KI-67
positive) compared with resting cells (Figure 3b), whereas
the central sub-population mainly consists of shrunken,
apoptotic or necrotic cells (TUNEL staining; Figure 3a),
forming the ‘necrotic’ center. This distribution of tumor cell
sub-populations is guaranteed by the spheroid sizes, being
due to a lack of nutrients and oxygen in the central part where
catabolic waste accumulates (Figure 3c).18 Successful
treatment of melanoma is particularly impaired by the fact
that metastatic disease quickly becomes resistant to
chemotherapy and combination therapies, respectively.19,20
Two proteins have recently been shown to confer chemo-
resistance specifically to melanoma cells: the ATP-dependent
drug efflux transporter ABCB521,22 and JARID1B, a histone
H3 demethylase that slows down the cell cycle.23,24
Comparing the expression levels of ABCB5 and JARID1B
in melanoma spheroids with primary cutaneous metastasis
revealed a similar expression pattern of both proteins.
In both tissues, only cells of the peripheral living populations
stained positive for ABCB5 (about 20%) and JARID1B (about
30%), further supporting the homology of the organotypic
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skin-melanoma spheroid model to in vivo metastasis
(Figures 3d and e).
Major impact of melanoma environment on therapeutic
response. The purpose of developing organotypic models
of cancer in vitro is to provide closer insight into tumor
physiology. It also allows to study both, therapeutic impact on
the tumor and side effects on the surrounding host tissue,
thereby serving the needs of reliable preclinical test systems.
In a previous monolayer-based study, we showed that 16 out
of 18 melanoma cell lines were synergistically sensitized to
TRAIL-induced apoptosis by co-application of sublethal UVB
radiation.13,14 Primary metastases, however, penetrate into
deeper, dermal parts of the skin and secondary metastases
invade even further into distant parts of the body which
cannot be reached by UVB.25 We therefore aimed to identify
an alternative stimulus to UVB as a TRAIL sensitizer
that would engage a similar biochemical mechanism to be
used systemically. Like UVB, cisplatin introduces base
modifications on DNA and consequently similar physiological
responses.26 Furthermore, cisplatin is known to sensitize
cancer cells from tissues of various origins to TRAIL-induced
apoptosis.27,28
When used at clinically achievable concentrations, cisplatin
sensitized resistant melanoma cells representing the three
major progression stages SBCL2 (RGP), WM-115 (VGP) and
451-LU (MM) to TRAIL-induced apoptosis, but to a considerably
lesser extent than UVB (Figure 4a). The molecular mechanism
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Figure 1 Generation of 3D organotypic skin equivalents. Paraffin sections of skin equivalents (a) compared with normal human skin (b) were H&E stained and
immunohistochemically analyzed for expression of keratins 14 and 10, involucrin, filaggrin and laminin 5. (c) Melanoma cells of different tumor progression stages, SBCL2
(RGP), WM115 (VGP) and 451-LU (MM), were seeded on top of the dermal layer before addition of keratinocytes. At day 17 of epidermal differentiation, the localization of
melanoma cells within the reconstituted skin equivalents was visualized by H&E staining of paraffin sections. Images show one representative out of three independently
performed experiments
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underlying TRAIL sensitization by cisplatin appeared similar
to the one responsible for UVB-induced TRAIL sensitiza-
tion.13,14 While combination with TRAILþUVB resulted in
pronounced XIAP depletion and caspase-3 processing,
combination of TRAIL with cisplatin only slightly affected this
process (Figure 4b).
A prerequisite for successful therapeutic strategies includes
that the primary host tissue remains less affected than the
tumor, or preferably unaffected. We could prove tumor
selectivity for TRAILþUVB and TRAILþ cisplatin combina-
tions, as they did not influence viability of primary fibroblasts
and melanocytes, and only slightly affected primary
keratinocytes in vitro, while selectively killing 451-LU mela-
noma cells (Figure 4c).
Our results show that, despite sharing certain aspects
with UVB-mediated TRAIL sensitization, the synergism of
cisplatin-induced TRAIL sensitization of melanoma cells is
less pronounced, at least in 2D cell culture. Given our intention
to compare the effectiveness of different therapeutic regimes
in the newly devised 3D skin-melanoma spheroid model, we
reckoned that the use of two related but different therapeutic
combinations could be highly informative. We therefore next
compared the therapeutic effects of the TRAILþ cisplatin and
TRAILþUVB combinations in both the skin-melanoma nest
and the skin-melanoma spheroid model.
Intriguingly, in the skin-melanoma nest model (Figure 4d;
Supplementary Figure S1) the outcome of TRAILþUVB
versus TRAILþ cisplatin treatment was significantly different
from that observed in 2D culture. Melanoma nests hosted
within organotypic skin remained largely unaffected by
individual treatment with TRAIL, UVB or cisplatin, but were
significantly reduced in number and size when treated with
TRAIL either in combination with UVB or cisplatin, both in
short-term and in long-term treatment schedules (Figure 4d).
Notably, whereas the tumoricidal effects of TRAILþUVB and
TRAILþ cisplatin were almost identical in long-term
treatment, in short-term treatment TRAILþ cisplatin was even
more potent than TRAILþUVB (Figure 4e). In both cases,
reduction in melanoma nests was mediated by selective
induction of apoptosis in tumor cells because only melanoma
nests that underwent combination treatment stained positive
for cleaved caspase-3, while normal keratinocytes and
fibroblasts were spared (Supplementary Figure S2). These
results show that, while the principle of sensitization of
melanoma cells to TRAIL-induced apoptosis by DNA-
damaging agents translates from 2D to 3D, the relative
potency of both combinations significantly varied in an
organotypic environment.
We next addressed how the texture of melanoma spheroids
affected tumor cell sensitivity to TRAIL-UVB versus TRAIL-
cisplatin co-treatment in vitro (Figure 5a). This analysis
showed that melanoma spheroids responded to treatments
combining TRAIL with UVB or cisplatin with apoptosis
induction and remained unaffected by individual treatments
as evidenced by AnnexinV/PI staining (Figure 5a;
Supplementary Figures S3a and b). Intriguingly, increased
FDA
PI
Figure 2 Generation of the organotypic melanoma-spheroid skin model. (a) 250 451-LU melanoma cells per 25ml drop RPMI medium were placed on the lid of a
non-adhesive PBS containing petri dish and incubated for 15 days deriving melanoma spheroids with a size of about 500mm in diameter. Live/death staining was performed by
incubation with 5 mg fluorescein diacetate (FDA) and 45 g propidium iodide (PI)/ml PBS for 20min at RT in the dark. Living cells stain FDA positive (green) and dead cells stain
PI positive (red). (b) Ten 451-LU spheroids were collected, carefully mixed with primary fibroblasts and added to collagen I to from the dermal compartment of the full thickness
skin equivalent
Figure 3 Melanoma spheroids resemble human melanoma metastasis. (a) Paraffin sections of tumor spheroids embedded into skin equivalents were stained for
proliferating (Ki67) and apoptotic (TUNEL) cells. (b) Statistical analysis of Ki67-positive cells of peripheral versus central sub-population within the spheroid. Mean±S.D. of
three different sections of three different spheroids are shown. (c) Scheme displaying cell sub-populations within a non-vascularized spheroid/tumor. (d) Sections of untreated
spheroid-containing skin equivalents and primary human cutaneous metastasis were stained for ABCB5 and JARID1B, respectively. Examples for ABCB5- or
JARID1B-positive cells are indicated by black arrows. (e) Statistical analysis of ABCB5- and JARID1B-positive cells of the peripheral sub-population within the spheroid
compared with human cutaneous metastasis. Mean±S.D. of three different sections of three different spheroids/metastasis are shown
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effectiveness of TRAILþ cisplatin as compared with TRAILþ
UVB in killing tumor cells was even further pronounced in
melanoma spheroids, reflected by advanced PI-positive
staining of spheroids as a marker for late apoptosis/necrosis.
These observations were corroborated by biochemical
analysis of melanoma spheroids, which showed that TRAILþ
cisplatin was substantially more effective in depleting XIAP
and, consequently, enabling full processing of caspase-3 than
TRAILþUVB (Figure 5b). This result confirmed the trend that
in more complex culture systems of melanoma, the synergism
of TRAILþ cisplatin becomes more pronounced whereas the
one of TRAILþUVB loses potency.
When finally analyzing the therapeutic effect of both
combinations in the skin-melanoma spheroid model, we
strikingly found that only TRAILþ cisplatin but not TRAILþ
UVB-induced apoptosis in melanoma spheroids at all (Figure 6).
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Figure 4 Combination treatment sensitizes melanoma cells but not primary cells to TRAIL. (a) SBCL2 (RGP), WM-115 (VGP) and 451-LU (MM) were stimulated with
TRAIL (100 ng/ml), cisplatin (20mM) or UVB (200 J/m2) alone, or the combination treatment. After 16 h, apoptosis was determined using a Cell Death Detection ELISA.
[R]¼ resistant; [s]¼ slightly sensitive; [S]¼ sensitive. *Po0.01 comparing co-treated with TRAIL-only-treated cells of the same line. (b) 451-LU cells (MM) were stimulated
as in (a). After 16 h, protein status of XIAP and cleavage pattern of caspase-3 were determined by western blot analysis. b-Actin served as loading control. One out of three
experiments is shown. (c) Primary fibroblasts, keratinocytes and melanocytes as well as 451-LU melanoma cells were treated and analyzed as in (a). Results in (a) and (c)
show the mean±S.D. of three independent experiments. (d) Skin equivalents containing 451-LU nests were subjected to either short-term treatment: TRAIL (250 ng/ml),
cisplatin (20 mM), UVB (400 J/m2) or in combination applied twice at days 13 and 15; or long-term treatment: TRAIL (250 ng/ml), cisplatin (2.5mM), UVB (200 J/m2) or in
combination applied five times over 10 days. At day 17, tumor volumes determined using ImageJ software. (e) Statistical analysis of tumor nest sizes counting the 10 largest
melanoma nests, and overall tumor nest numbers (mean±S.D.) of three sections of skin equivalents derived from five different donors. *Po0.05, **Po0.01 comparing
co-treated with TRAIL-only-treated tumor nests
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Apoptosis induction by TRAILþ cisplatin was selective for
proliferating cells within the melanoma spheroids (Figures 6d
and f). Treatments with TRAIL, UVB and cisplatin alone, or
with TRAILþUVB, did not significantly affect cell viability
(Figures 6b, c and e). Importantly, the disability of UVB to
sensitize melanoma cells in skin-embedded spheroids to
TRAIL-induced apoptosis was not due to its insufficient tissue
penetration, as cyclobutane pyrimidine dimers (CDP), gener-
ated as a result of UVB irradiation, were readily detectable
even in deeper parts of the dermis (Supplementary Figure
S4). TRAILþ cisplatin co-treatment resulted in almost com-
plete disappearance of Ki67-positive melanoma cells from the
peripheral sub-population of skin reconstruct-embedded
melanoma spheroids, while, concomitantly, most cells stained
positive for cleaved caspase-3 and TUNEL (Figure 6f). Yet,
hardly any changes could be detected in spheroids following
TRAILþUVB co-treatment (Figure 6d). Like in the skin-
melanoma nest model, the pro-apoptotic effect of TRAILþ
cisplatin was tumor selective in the skin-melanoma spheroid
model, as most primary human fibroblasts and keratinocytes
survived (zoomed Figure 6f). Hence, whereas TRAILþ
cisplatin exert a substantial apoptotic effect in the newly
devised skin-melanoma spheroid model, TRAILþUVB does
not. Accordingly, the organotypic environment appears to
influence the therapeutic outcome. These results show that
diametric differences in therapeutic efficiency of two related
therapeutic concepts are likely to exist between conventional
2D cell culture and more sophisticated organotypic 3D
models. It furthermore offers the combination therapy of
TRAILþ cisplatin to become a promising strategy to fight
melanoma.
Discussion
A multitude of clinical trials conducted so far has not achieved
significant benefit for patients with MM. Despite remarkable
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Figure 5 Melanoma spheroids respond to combination treatment in vitro. (a) Melanoma spheroids were left untreated or stimulated with TRAIL (100 ng/ml), cisplatin
(20mM), UVB (200 J/m2) or a combination thereof. Twenty hours later, spheroids were stained for apoptosis using FITC-labeled AnnexinV (green) and propidium iodide
(PI; red) and analyzed by immunofluorescence microscopy. Nuclei were visualized with Hoechst 33342 (blue). (b) Melanoma spheroids were treated as in (a). Sixteen hours
later, the protein status of XIAP and cleavage pattern of caspase-3 were determined by western blot analysis. b-Actin served as loading control. One out of three
independently performed experiments is shown
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Figure 6 Melanoma spheroids integrated into skin equivalents respond to TRAILþ cisplatin but not to TRAILþUVB. Organotypic skin equivalents containing 451-LU
spheroids were left (a) untreated or subjected to short-term treatment with (b) TRAIL (500 ng/ml), (c) UVB (400 J/m2) or (e) cisplatin (40mM) alone or in (d) TRAILþUVB and
(f) TRAILþ cispatin combination, respectively, applied twice on days 13 and 15. On day 17, paraffin sections were stained for Ki67, cleaved caspase-3 and TUNEL positivity,
respectively. One representative out of three independently performed experiments is shown
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effort and promising in vitro activities, this disease remains
almost invariably lethal. It therefore appears that a more
thorough and reliable preclinical evaluation of novel drugs and
therapeutic combination will be essential to reduce attrition
rates in clinical trials and improve the benefit from therapeutic
interventions. Mouse models so far have not gained sub-
stantial clinical benefit,29 because the architecture of mouse
skin significantly differs from human skin. Given the need for
better suitable in vitro test systems, we have generated a full
thickness organotypic human skin model that displays a
differentiation status homologous to normal human skin.30
Aiming to decode the molecular mechanisms decisive for
melanoma resistance, we took advantage of large and
differentiated tumor spheroids which, when integrated into
organotypic skin reconstructs, histologically show high
similarity to primary cutaneous human melanoma
metastases. This includes a necrotic center and the existence
of similar numbers of ABCB5- and JARID1B-expressing
cells—features thought to majorly contribute to the
relapse of initially responding tumors. The percentages of
JARID1B- and ABCB5-positive cells counted here were
higher, both in vitro and in vivo, compared with previous
reports.24 However, we refer to the percentage of the vital cell
population, not of the whole tumor population. The degree of
cellular differentiation we observe is neither reflected in
2D cell culture nor sufficiently addressed in 3D models
incorporating tumor nests. Up to a size of 150–200 mm all
cells contained with a spheroid can still be sufficiently supplied
with nutrients via simple diffusion. Only spheroids with
sizes of/above 500mm represent typical features of non-
vascularized tumor tissue.16,31
To date, conventional chemotherapy-based cancer treat-
ment is increasingly seconded by the application of targeted
therapeutics, for example, inhibitors of kinases,32 the
proteasome33 or NF-kB activation,34 as well as drugs targeting
apoptotic pathways, including Smac and BH3 mimetics35 and
agonists of apoptosis-inducing TRAIL receptors.36 Still, many
melanoma cell lines were shown to be resistant against TRAIL-
induced apoptosis.13,37 While TRAILþUVB was more potent
at inducing apoptosis in 2D culture than TRAILþ cisplatin,
increasing complexity of the screening model completely
shifted the balance in favor of TRAILþ cisplatin. Importantly,
in the most advanced 3D organotypic skin-melanoma spheroid
model the therapeutic effect of TRAILþUVB was virtually lost
whereas the one of TRAILþ cisplatin increased substantially.
Accordingly, application of this model shows that insights
gained from 2D melanoma culture cannot readily be translated
to complex 3D skin-melanoma models, and it implies that the
tumor environment decisively impacts the response to therapy.
It appears that the organotypic 3D human skin-melanoma
spheroid model developed here provides an environment that
more closely resembles the physiology of human malignant
melanoma than previously available systems and may there-
fore set milestones for the study and understanding of this
malignancy.
The environment of melanoma in patients is, however, even
more complex; besides tumor-associated fibroblast, the
microenvironment of human melanoma comprises various
other non-transformed cell types, including immune cells and
endothelial cells. The skin-melanoma spheroid model will
serve as a basis for constructing models that integrate
additional cell types present in the melanoma microenviron-
ment, and may also be suitable to host other types of cancer.
Therapeutically, the 3D skin-melanoma spheroid model will
be useful for short-term screening of primary melanoma cells
freshly isolated from patients. One can envisage the inclusion
of spheroids derived from primary human melanoma
(Supplementary Figure S5) or even of pieces of melanoma
metastases. Thereby, preclinical testing of therapeutic com-
binations in the context of a known genetic make-up of a given
melanoma (e.g., BRAF mutation) would be enabled, paving
the path to more personalized approaches in melanoma
therapy. In this context, an increasing complexity of the model
will offer a useful platform to study the impact of soluble
factors, like cytokines or RTK ligands released from tumor
cells or surrounding host cells, that have been shown to
influence the therapeutic outcome of melanoma.38
Including the organotypic 3D skin-melanoma model into the
preclinical testing repertoire is likely to provide that only the
most promising novel therapeutic concepts are taken forward
into clinical testing so that, in the future, the attrition rate of
potential new treatments for this disease may be reduced and
their rate of success in clinical trials increased.
Materials and Methods
Cells and Reagents. Human melanoma cell lines SBCL2 (RGP), WM-115
(VGP) and 451-LU (MM) were kindly provided by Dr. Friedegund Meier,
Department of Dermatology, University of Tu¨bingen. Cells were maintained in
RPMI-1640 (Life Technologies, Karlsruhe, Germany), 10% FCS (Thermo
Scientific, Langenselbold, Germany) and 1% penicillin–streptomycin (Life
Technologies) at 371C, 5% CO2. Keratinocytes were prepared from the epidermis
and fibroblasts form the dermis of juvenile human foreskin,39 Melanocytes were
prepared from adult skin.40 Keratinocytes were maintained in KGM 2 (PromoCell,
Heidelberg, Germany), passaged at 50–70% confluency and used at passage
four. Fibroblasts were cultivated in high-glucose DMEM (Life Technologies),
Melanocytes in M2 (PromoCell) and assayed in passage four. UVB irradiation was
performed in PBS using a bank of six TL12 bulbs (Phillips, Eindhoven,
Netherlands), emitting most of the energy within the UVB range (emission peak at
313 nm). Recombinant human iz-TRAIL protein was prepared as previously
described.41 Cisplatin was obtained from Platinex (Bristol, UK).
Generation and treatment of melanoma spheroids. Melanoma
spheroids were generated via the ‘hanging drop’ method incorporating 250
melanoma cells per 25ml RPMI placed on the lid of a non-adhesive PBS
containing petri dish.15 Spheroids were incubated for 15 days at 371C, 5% CO2.
Every third day, 8 ml of the medium per drop was exchanged. For in vitro
stimulation, spheroids were harvested and maintained in a non-adhesive petri
dish. Nuclei were stained with 1 mg/ml Hoechst 33342 (Sigma, Munich, Germany)
for 30min at RT. Apoptosis was determined by staining the spheroids with
0.375mg/ml FITC-labeled Annexin V (MBL, Woburn, MA, USA) and 0.6mg/ml PI
(Sigma) in binding buffer (10mM HEPES, pH 7.4; 140mM NaCl; 2.5 mM CaCl2)
for 20min at RT in the dark. Stained spheroids were analyzed in CELLview dishes
(Greiner-bio-one, Stuttgart, Germany) via confocal microscopy (LSM 710; Zeiss,
Munich, Germany) with 1 airy aperture and a resolution of 1024 1024 pixel.
Z-stacks were taken and further analyzed using ZEN 2009 smart setup software
(Zeiss).
Generation of skin models. Skin models were generated using 24-well
inserts (Nunclon TM D; Nunc, Rochester, NY, USA) in 24-well plates
(Greiner-bio-one). Per insert 1 105 fibroblasts in GNL (322.5ml 2DMEM;
7.5 ml 3 M HEPES; 1.25 ml chondroitin-4-sulfate; 1.25 ml chondroitin-6-sulfate;
7.5 ml FCS) were mixed 1 : 3 with collagen I isolated from rat tails to a final volume
of 500ml and cultivated in DMEM/4.5 g/l glucose/1% L-glutamine/10% FCS/L-
pyruvate overnight at 371C. Next day, dermal gels were equilibrated with EGM/10%
FCS/1% PenStrep/10mg/ml gentamycine42 for 2 h at 371C. The medium was
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withdrawn and 1 105 keratinocytes in EGM43,44 carefully seeded on top and
incubated for 1.5 h at 371C to allow adhesion. Subsequently, skin equivalent was
covered with EGM and cultivated for 7 days—changing the medium every other
day. At day 7, skin equivalents were transferred to 6-well plates and cultivated/
treated at the air–liquid interface in MM43,44 for 17 more days at 371C, changing
the medium every other day. For generation of melanoma nests 104 451-LU cells
were seeded onto the dermal layer 1 h before keratinocytes were added.
Alternatively, 10 tumor spheroids were added to fibroblasts containing GNL and
mixed with collagen I as above.
Immunohistochemical analyses of organotypic skin
equivalents. Skin models were fixed in Roti-Histofix (Roth, Karlsruhe,
Germany) for 3 h at RT released from the insert and embedded into paraffin.
Sections of 3 mm were cut using an RM 2145-microtome (Leica, Biberach,
Germany), transferred onto slides (LABOnord; Greiner-bio-one) for hematoxylin-eosin
(HE) staining or onto sialynized slides (Menzel GmbH, Braunschweig, Germany)
for immunohistochemical analysis and dried at 371C overnight. Sections were
released from paraffin using Roticlear (Roth) and subjected to HE staining at
RT or were incubated with primary antibodies against caspase-3 (#9446; Cell
Signaling, Beverly, MA, USA), S100B (330M-15; Cell Marque, Rocklin, CA, USA),
ABCB5 (Sigma), Ki67, keratin 10 (Dako, Hamburg, Germany), keratin 14, laminin
5 (Santa Cruz, Heidelberg, Germany), filaggrin (Biomedia, Singapore) and involucrin
(Acris, Herford, Germany), respectively, as recommended by the manufacturer at 41C
overnight. For peroxidase detection, anti-mouse or anti-rabbit antibodies (EnVision;
Dako) were incubated for 30min at RT and liquid DABþ substrate chromogen
substrate (Dako) added for up to 10min at RT. Slides were fixed with Isomount 2000
(LABOnord) and analyzed microscopically (Axiovert 200M, AxioCam HRc; Zeiss). For
immunofluorescence analysis, secondary polyclonal goat-anti-mouse-FITC (Dako) or
goat-anti-mouse-Cy3 IgG, Newmarket, UK (Jackson ImmunoResearch, Newmarket,
UK) antibodies were used, slides mounted in ProLong Gold with or without DAPI
(Molecular Probes Life Technologies, Darmstadt, Germany) and analyzed using a
confocal microscope (LSM 710, ZEN 2009 software; Zeiss) or fluorescence
microscope for spheroids (Zeiss Axiovert 200M, Axio vision rel. 4.8 software; Zeiss).
TUNEL staining was performed using an In Situ Cell Death Detection Kit (Roche;
Mannheim, Germany). Sections from human cutaneous metastasis were kindly
provided by the Clinic of Dermatology, University of Dresden and treated as above.
Volumes of melanoma nests were determined using ImageJ (NIH) software,
calculating the 10 largest nests of individual sections.
Determination of cell death. Apoptosis was measured using a Cell Death
Detection ELISA kit (Roche). The enrichment of mono- and oligo-nucleosomes
released into the cytoplasm is calculated as: absorbance of sample cells/
absorbance of control cells. The enrichment factor of 2 corresponds to 10%
apoptotic cells as determined by AnnexinV-FITC staining and FACS analysis.
Western blot analysis. Cells were lysed in lysis buffer (50mM Hepes,
pH 7.5; 150 mM NaCl; 10% glycerol; 1% Triton X-100; 1.5 mM MgCl2; 1 mM
EGTA; 100mM NaF; 10mM pyrophosphate, 0.01% NaN3 and Complete, Roche),
tumor spheroids were disrupted by sonication in lysis buffer and the protein
content was determined by DC Bio-Rad Protein assay kit (Bio-Rad, Hercules, CA,
USA). In all, 60–80mg of protein samples was subjected to 13–15% SDS-PAGE,
and western blot analysis using antibodies directed against caspase-3, (#9662;
Cell Signaling), XIAP (#610716; BD Biosciences, Heidelberg, Germany) or b-actin
(Sigma). Protein bands were visualized with HRP-conjugated secondary
antibodies (Amersham, Buckinghamshire, UK) in a chemiluminescent reaction
(SuperSignal; PIERCE, Rockford, IL, USA).
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